Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.09
+0.51006.73%
Post-market: 8.110.0209+0.26%19:58 EDT
Volume:7.21M
Turnover:58.70M
Market Cap:837.99M
PE:-1.55
High:8.40
Open:7.79
Low:7.75
Close:7.58
Loading ...

Intellia Therapeutics Q4 Basic EPS USD -1.27

THOMSON REUTERS
·
27 Feb

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Intellia Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Reuters
·
25 Feb

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks
·
24 Feb

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

Zacks
·
18 Feb

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Simply Wall St.
·
15 Feb

NTLA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

TIPRANKS
·
12 Feb

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey
·
07 Feb

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
28 Jan

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires Live
·
28 Jan

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

MT Newswires Live
·
27 Jan

Intellia Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
27 Jan

Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

TIPRANKS
·
27 Jan

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks
·
23 Jan

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

MT Newswires Live
·
22 Jan

Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002

TIPRANKS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

THOMSON REUTERS
·
22 Jan